Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006, 150(2):235-237 | DOI: 10.5507/bp.2006.033

EVALUATION OF URINE N1,N12-DIACETYLSPERMINE AS POTENTIAL TUMOR MARKER FOR URINARY BLADDER CANCER

David Stejskala, Viera Humenanskab, Zuzana Hanulovab, Richard Fialac, Radovan Vrtalc, Pavlina Solichovaa, Michal Karpisekd
a Department of Laboratory Medicine, Sternberk Hospital, Czech Republic
b Gnosis s.r.o., Bratislava, Slovakia
c Department of Urology, Faculty Hospital Olomouc
d University of Veterinary and Pharmaceutical Sciences, Brno

Background: N1,N12-diacetylspermine, a diacetylpolyamine which was recently identified in urine, appeared to be a useful tumor marker for a number of cancers. No valid data on urine diacetylspermine concentration in patients with urinary bladder cancer exist.

Aim: Evaluation of urine N1,N12-diacetylspermine concentrations in individuals with urinary bladder cancer.

Methods: Urine samples were used from 36 patients with urothelial tumors of the urinary bladder and from 30 patients with benign urological diseases. Urine was collected before cystoscopy. Enzyme-linked immunoabsorbent assays (ELISA) were performed for diacetylspermine from urine.

Results: Urine diacetylspermine did not differentiate in individuals with urinary bladder cancer from controls (medians 171.5 vs 143.8, p = 0.64). Its efficacy for urinary bladder cancer detection was not shown.

Conclusions: Urine N1,N12-diacetylspermine is probably not a useful marker for urinary bladder cancer.

Keywords: Urine N1,N12-Diacetylspermine, Urinary Bladder Cancer, ELISA

Received: September 3, 2006; Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stejskal, D., Humenanska, V., Hanulova, Z., Fiala, R., Vrtal, R., Solichova, P., & Karpisek, M. (2006). EVALUATION OF URINE N1,N12-DIACETYLSPERMINE AS POTENTIAL TUMOR MARKER FOR URINARY BLADDER CANCER. Biomedical papers, 150(2), 235-237. doi: 10.5507/bp.2006.033
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ozen H, Hall MC. Bladder cancer. Curr Opin Oncol 2000; 12:255- 9. Go to original source... Go to PubMed...
    2. Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front. Biosci 2002; 7:36-1. Go to original source... Go to PubMed...
    3. Stein JP, Grossfeld GD, Ginsberg DA. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160:645-59. Go to original source... Go to PubMed...
    4. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a dissappointing senzitivity for small size and low grade reccurence. J Urol 2002; 167:80-3. Go to original source... Go to PubMed...
    5. Pode D, Golijanin D, Sherman Y. Immunostaining of Lewis X in cells from voided urine. J.Urol 1998; 159:389-2. Go to original source... Go to PubMed...
    6. Sarosdy MF, de Vere White RV, Soloway MS. Results of multicentric trial using the BTA test to monitor for and diagnose reccurent bladder cancer. J.Urol 1995; 154:379-3. Go to original source... Go to PubMed...
    7. Soloway MA, Briggman JV, Carpinito GA. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurrent transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156:363-7. Go to original source... Go to PubMed...
    8. Friedrich MG, Helstern A, Toma MI. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? EurUrol 2003; 43:146-1. Go to original source... Go to PubMed...
    9. Mirkin BL, Clark S, Zheng X, Chu F. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 2005; 24:4965-4. Go to original source... Go to PubMed...
    10. Munz M, Zeidler R, Aires O. The tumor-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Canc Let 2005; 225:151-7. Go to original source... Go to PubMed...
    11. Schmidt A, Sommer F, Reiner M. Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int 2005; 95:174-9. Go to original source... Go to PubMed...
    12. Du Z, Hou S. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 2003; 170:2000-3. Go to original source... Go to PubMed...
    13. Kawakita M, Hiramatsu K. Diacetylated derivatives of spermine and spermidine as novel promising tumor markers. J Biochem 2006; 139:315-2. Go to original source... Go to PubMed...
    14. Kawakita M, Hiramatsu K, Sugimoto M. Clinical usefulness of urinary diacetylpolyamines as novel tumor markers. Rinsho Byori 2004; 52:321-7. Go to PubMed...
    15. Enjoji M, Nakamuta M, Arimura E. Clinical significance of urinary N1,N12-diacetylspermine levels in patients with hepatocellular carcinoma. Int J Biol Markers 2004; 19:322-7. Go to original source... Go to PubMed...
    16. Sugimoto M, Hiramatsu K, Kamei S. Significance of urinary N1,N8- diacetylspermidine and N1,N12-diacetylspermine as indicators of neoplastic diseases. J Cancer Res Clin Oncol 1995; 121:317-9. Go to original source... Go to PubMed...
    17. Kubota S, Yamasaki Z, Yoshimoto M.The value of urinary polyamine assay in stomach cancer. Comparison with serum carcinoembryonic antigen. Cancer 1985; 56:1630-1635. Go to original source... Go to PubMed...
    18. Kee K, Vujcic S, Merali S. Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. J Biol Chem 2004; 279:27050-8. Go to original source... Go to PubMed...
    19. In: http://www.biovendor.com

    Return to the content